Get started
Author

Jan H. ter Meulen

Observed names: Jan H. Ter Meulen, Jan Henrik ter Meulen
OpenAlex ID: A5011895674
The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease
2011 · Beth-Ann G. Coller, David E. Clements, et al. · Vaccine · 141
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2019 · Neeta Somaiah, Matthew S. Block, et al. · Clinical Cancer Research · 87
Trial Watch
2014 · Fernando Aranda, Erika Vacchelli, et al. · OncoImmunology · 81
PDF
Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates
2015 · Dhanasekaran Govindarajan, Steven Meschino, et al. · Vaccine · 75
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1
2019 · Amit Mahipal, Samuel Ejadi, et al. · Cancer Immunology Immunotherapy · 28
HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells
2017 · Edmund G. Wee, Beatrice Ondondo, et al. · Molecular Therapy · 20
PDF
In vitro and in vivo inhibitory effects of TLR4 agonist, glucopyranosyl lipid A (GLA), on allergic rhinitis caused by Japanese cedar pollen
2019 · Koji Matsumoto, Hideaki Kouzaki, et al. · Allergy · 12
Toll-Like Receptor 4 Expression on Lymphoma Cells Is Critical for Therapeutic Activity of Intratumoral Therapy With Synthetic TLR4 Agonist Glucopyranosyl Lipid A
2020 · Hailing Lu, Alec Betancur, et al. · Frontiers in Oncology · 11
PDF
Effect of intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist G100 on a clinical response and CD4 T-cell response locally and systemically.
2018 · Yongwoo David Seo, Jing Zhou, et al. · Journal of Clinical Oncology · 4
Abstract 2505: Therapeutic efficacy of the ZVex™ and GLAAS™ platforms in a B16-F10/hCAIX melanoma mouse model
2015 · David J. Campbell, Rebecca S. Reeves, et al. · Cancer Research · 1
Table S2 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Figure S1 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Table S1 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Figure S1 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Table S1 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Data from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Data from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Table S2 from First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
2023 · Neeta Somaiah, Matthew S. Block, et al.
Filoviruses
2020 · Jan H. ter Meulen
Arenaviruses
2020 · Jan H. ter Meulen
Abstract 5919: Component-specific qPCR assays for characterization and identity testing of multigenome ZVex®, a dendritic cell-targeting lentiviral vector platform
2018 · Anshika Bajaj, Tsai-Yu Lin, et al. · Cancer Research
Abstract 2506: Preclinical characterization of LV305, a lentiviral vector targeting tumors expressing NY-ESO-1
2015 · Tina C. Albershardt, David J. Campbell, et al. · Cancer Research
Abstract 702: DCVex(TM): A novel integration-deficient lentivector technology that incorporates genetic and post-translational elements to target dendritic cells
2014 · Semih U. Tareen, Brenna Kelley-Clarke, et al. · Cancer Research
Abstract 2817: DCVex(TM): A novel DC-targeted vector platform for cancer immunotherapy
2014 · Tina C. Albershardt, Semih U. Tareen, et al. · Cancer Research
Works count: 24
Citation count: 460
H-index: 8
I10-index: 8
Year
Topic
Type